Opening stock page...
Fetching company snapshot, pricing, and intelligence.
AI confidence 70% · prior close shown (market closed)
AGILENT TECHNOLOGIES, INC. shows decelerating business momentum based on AlphaOS pipeline evidence.
Why it matters: Revenue +8% YoY in Q3 FY2026.
1 signal not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 1d ago
A's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on A.
Free accounts see more of this; Premium sees all of it.
Reported figures for AGILENT TECHNOLOGIES, INC. — research only, not investment advice.
Updated
What happened recently for AGILENT TECHNOLOGIES, INC. (A) — events, not interpretation.
Research & analysis only — not investment advice.
AlphaOS industries
Investment snapshot
A's AI investment thesis
Upgrade to Premium for A's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$172.79
Market cap
$48.71B
Profitable
Yes
Revenue $1.88B
Net income
$362.00M
FY Sep 27, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for AGILENT TECHNOLOGIES, INC. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow AGILENT TECHNOLOGIES, INC. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.
Structured stock intelligence for companies connected to this research.
The shift from broad-spectrum drugs to gene-level targeting is concentrating value in a surprisingly narrow set of platform companies.
The biggest gains aren't in blockbuster drugs — they're in the infrastructure that makes every drug possible.
The tools to read, edit, and deliver on the genome are maturing faster than the market prices in.
The edge in healthcare no longer belongs to the biggest drug pipelines — it belongs to the most targeted ones.
Gene editing and mRNA platforms are moving from research curiosity to approved therapies faster than the market expected.
Breakthroughs in gene editing and targeted therapies are reshaping healthcare landscapes.